Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Miki Horiguchi"'
Autor:
Gabriella Geiger, Lauren Kiel, Miki Horiguchi, Celia Martinez-Aceves, Kelly Meza, Briana Christophers, Priscilla Orellana, Maria Mora Pinzon, Sam J. Lubner, Narjust Florez
Publikováno v:
BMC Medical Education, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background The percentage of physicians identifying as Latina has not improved despite improvements in recruitment of Latina medical students, suggesting barriers to retention and career advancement. Discriminatory experiences and mental hea
Externí odkaz:
https://doaj.org/article/472e5361c3834296a42f2640e1c88a92
Publikováno v:
Statistics in Medicine. 42:1139-1155
Autor:
Matthew B. Yurgelun, Hajime Uno, C. Sloane Furniss, Chinedu Ukaegbu, Miki Horiguchi, Amal Yussuf, Holly LaDuca, Anu Chittenden, Judy E. Garber, Sapna Syngal
Publikováno v:
Journal of Clinical Oncology. 40:4083-4094
PURPOSE With the availability of multigene panel testing (MGPT) for hereditary cancer risk assessment, clinicians need to assess the likelihood of pathogenic germline variants (PGVs) across numerous genes in parallel. This study's aim was to develop
Autor:
Dame Idossa, Ana I. Velazquez, Miki Horiguchi, Julia Alberth, Inas Abuali, Demetria Smith-Graziani, Gilberto de Lima Lopes, Sam Lubner, Narjust Florez
Publikováno v:
JCO Oncology Practice.
PURPOSE Physician workforce diversity can be a driver of institutional excellence, improving innovation and reducing health disparities. However, the current diversity of the hematology/oncology (HO) workforce does not reflect that of the US populati
Autor:
Connie S. Zhong, Miki Horiguchi, Hajime Uno, Chinedu Ukaegbu, Anu Chittenden, Nicole R. LeBoeuf, Sapna Syngal, Vinod E. Nambudiri, Matthew B. Yurgelun
Publikováno v:
Journal of the American Academy of Dermatology.
Autor:
Miki Horiguchi, Hajime Uno
Publikováno v:
Statistics in medicineREFERENCES.
The hazard ratio (HR) has been the most popular measure to quantify the magnitude of treatment effect on time-to-event outcomes in clinical research. However, the traditional Cox's HR approach has several drawbacks. One major issue is that there is n
Autor:
Tara Fehlmann, Matthew B. Yurgelun, C. Sloane Furniss, Chinedu Ukaegbu, Hajime Uno, Alessandro Mannucci, Sapna Syngal, Miki Horiguchi
Publikováno v:
Journal of Clinical Oncology. 38:4086-4094
PURPOSE Tumor testing for microsatellite instability and/or mismatch repair-deficiency (MSI/IHC) and clinical prediction models effectively screen for Lynch syndrome (LS)–associated colorectal cancer (CRC) and endometrial cancer (EC), but they have
Autor:
Nicolette J. Rodriguez, C. Sloane Furniss, Matthew B. Yurgelun, Chinedu Ukaegbu, Pamela E. Constantinou, Ileana Fortes, Alyson Caruso, Alison N. Schwartz, Jill E. Stopfer, Meghan Underhill-Blazey, Barbara Kenner, Scott H. Nelson, Sydney Okumura, Alicia Y. Zhou, Tara B. Coffin, Hajime Uno, Miki Horiguchi, Allyson J. Ocean, Florencia McAllister, Andrew M. Lowy, Scott M. Lippman, Alison P. Klein, Lisa Madlensky, Gloria M. Petersen, Judy E. Garber, Michael G. Goggins, Anirban Maitra, Sapna Syngal
Publikováno v:
Cancer Research. 82:A029-A029
Background: Uptake of genetic testing for cancer susceptibility in family members of cancer patients is suboptimal. The GENetic Education, Risk Assessment, and TEsting (GENERATE) study evaluated two strategies of remote genetic education and testing
Publikováno v:
The Oncologist. 25:91-93
There exist a wide variety of statistical methods for clinical trials. Despite decades of clinical trial research, little is known about which methods are used in data analysis practice of the real world. This review describes the evidence of existin
Autor:
Dame Idossa, Ana I. Velazquez Manana, Miki Horiguchi, Julia Alberth, Inas Abuali, Demetria Joy Smith-Graziani, Gilberto Lopes, Sam Joseph Lubner, Narjust Duma
Publikováno v:
Journal of Clinical Oncology. 40:11047-11047
11047 Background: Physician workforce diversity can be a driver of institutional excellence, improving innovation and reducing health disparities. The current diversity of the hematology/oncology (HO) workforce does not reflect that of the US populat